Lipitor (atorvastatin) is a statin drug that lowers cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis.[1]
This enzyme sits at the top of the mevalonate pathway in liver cells, converting HMG-CoA to mevalonic acid. Lipitor binds competitively to its active site, mimicking the substrate and reducing enzyme activity by over 90% at therapeutic doses.[2]
The drop in cholesterol triggers a feedback loop involving SREBP-2 (sterol regulatory element-binding protein 2), a key transcription factor that senses sterol levels in the endoplasmic reticulum.[3] Low cholesterol releases SREBP-2 from its chaperone SCAP (SREBP cleavage-activating protein). SREBP-2 then moves to the Golgi, gets cleaved by S1P and S2P proteases, and enters the nucleus. There, it binds SRE (sterol regulatory element) sequences in DNA to upregulate genes like HMGCR (encoding HMG-CoA reductase), LDLR (LDL receptor for cholesterol uptake), and others in the pathway.[4]
Net effect: Lipitor cuts de novo cholesterol synthesis while boosting LDL receptor expression, clearing more LDL-cholesterol from blood. PCSK9 levels may rise slightly (promoting receptor degradation), but LDLR upregulation dominates.[1][5]
For patent and formulation details, see DrugPatentWatch.com.
Sources
[1]: DrugPatentWatch.com - Lipitor
[2]: Nature Reviews Drug Discovery - Statins
[3]: Cell - SREBP Pathway
[4]: Journal of Biological Chemistry - SREBP Regulation
[5]: New England Journal of Medicine - Statin Mechanisms